Omeprazol Krka (Omeprazole)

Omeprazol Krka is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions:

• Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of esophageal erosion.
• Peptic ulcer disease: supports ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production.
• Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.
• NSAID‑induced ulcer prophylaxis: lowers risk of ulcer development in high‑risk patients.

• Omeprazole irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells, inhibiting the final step of acid secretion. This blockade reduces both basal and stimulated gastric acid output, allowing the gastric mucosa to heal and decreasing reflux of acidic contents into the esophagus.

Adverse reactions to Omeprazole may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Headache: mild, transient headache reported in clinical use.
• Diarrhea: loose stools occurring early in treatment.
• Abdominal pain: mild discomfort or cramping.
• Nausea: occasional feeling of queasiness.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis linked to altered gut flora.
• Acute interstitial nephritis: sudden kidney inflammation.
• Hypomagnesemia: low serum magnesium with prolonged use.
• Stevens‑Johnson syndrome: rare severe skin reaction.
• Fracture risk: increased risk of hip, wrist or spine fractures with long‑term use.
• Liver enzyme elevation: raised ALT/AST levels indicating hepatic stress.

When prescribing Omeprazole, clinicians should consider several safety aspects:

• Assess renal function: adjust use in patients with severe kidney impairment.
• Evaluate liver status: use cautiously in hepatic disease.
• Review concomitant medications: potential for drug‑drug interactions.
• Monitor long‑term use: consider step‑down therapy after symptom control.
• Pregnancy and lactation: weigh benefits against potential risks.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs. Awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular events.
• Atazanavir: decreased absorption, loss of antiviral efficacy.
• Dasatinib: lowered plasma concentrations, reduced therapeutic effect.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, monitor coagulation parameters.
• Phenytoin: decreased serum levels, watch for seizure control.
• Digoxin: possible rise in serum digoxin, check levels periodically.